14.95

4.18% 0.60

After Hours: 15.01 0.06 +0.40%

Cullinan Therapeutics Inc (CGEM)

Overview News Price History Option Chain Financials Discussions Forecast

Cullinan Therapeutics Inc stock is traded at $14.95, with a volume of 977.83K. It is up +4.18% in the last 24 hours and up +10.82% over the past month. Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Previous Close:

$14.35

Open:

$14.41

24h Volume:

977.83K

Relative Volume:

1.24

Market Cap:

$904.87M

Revenue:

Net Income/Loss:

$-219.88M

P/E Ratio:

-4.0147

EPS:

-3.7238

Net Cash Flow:

$-175.76M

1W Performance:

-0.07%

1M Performance:

+10.82%

6M Performance:

+73.23%

1Y Performance:

+91.67%

1-Day Range:

$14.40

$15.10

1-Week Range:

$13.75

$15.31

52-Week Range:

$5.68

$16.74

Cullinan Therapeutics Inc Stock (CGEM) Company Profile

Name

Cullinan Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

617-410-4650

Address

ONE MAIN STREET, CAMBRIDGE

Employee

109

Twitter

Next Earnings Date

2026-03-12

Latest SEC Filings

CGEM's Discussions on Twitter

Compare CGEM vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CGEM Cullinan Therapeutics Inc	14.95	868.55M	0	-219.88M	-175.76M	-3.7238
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-17-26	Initiated	Citigroup	Buy
Feb-02-26	Initiated	Guggenheim	Buy
Aug-21-25	Resumed	H.C. Wainwright	Buy
Jun-11-25	Resumed	Stifel	Buy
Oct-24-24	Initiated	UBS	Buy
May-01-24	Initiated	Stifel	Buy
Apr-15-24	Initiated	William Blair	Outperform
Feb-15-24	Initiated	Wedbush	Outperform
Jun-15-23	Initiated	TD Cowen	Outperform
Nov-21-22	Initiated	BTIG Research	Buy
Apr-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Feb-02-21	Initiated	Evercore ISI	Outperform
Feb-02-21	Initiated	Morgan Stanley	Equal-Weight
Feb-02-21	Initiated	SVB Leerink	Outperform
Feb-01-21	Initiated	H.C. Wainwright	Buy

View All

Cullinan Therapeutics Inc Stock (CGEM) Latest News

Apr 13, 2026

Patterns Watch: Can Bausch Health Companies Inc expand into new markets - baoquankhu1.vn

Apr 13, 2026

Macro Review: Can Cullinan Therapeutics Inc benefit from deglobalization2026 Biggest Moves & Community Verified Watchlist Alerts - baoquankhu1.vn

Apr 13, 2026

Apr 10, 2026

Signal Recap: Whats the RSI of Cullinan Therapeutics Inc stock2026 Highlights & Real-Time Sentiment Analysis - baoquankhu1.vn

Apr 10, 2026

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Apr 10, 2026

Apr 07, 2026

Weekly Earnings: What is Cullinan Therapeutics Incs valuation compared to sectorWeekly Trading Summary & AI Based Trade Execution Alerts - baoquankhu1.vn

Apr 07, 2026

Apr 06, 2026

JonesTrading Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $36 - Moomoo

Apr 06, 2026

Bull Run: Whats the profit margin of Cullinan Therapeutics Inc2026 Fundamental Recap & Reliable Breakout Stock Forecasts - baoquankhu1.vn

Apr 06, 2026

Cullinan Therapeutics (NASDAQ:CGEM) Shares Up 6.3%What's Next? - MarketBeat

Apr 06, 2026

Apr 05, 2026

Can Cullinan Therapeutics Inc outperform under higher oil prices2026 Setups & Free Daily Entry Point Trade Alerts - baoquankhu1.vn

Apr 05, 2026

Apr 01, 2026

CGEM SEC FilingsCullinan Oncology Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 01, 2026

Mar 28, 2026

Cullinan Therapeutics (NASDAQ:CGEM) versus Genprex (NASDAQ:GNPX) Head to Head Comparison - defenseworld.net

Mar 28, 2026

Mar 26, 2026

Vanguard disaggregates holdings; reports 0 shares of Cullinan Therapeutics (CGEM) - Stock Titan

Mar 26, 2026

Volume Summary: Will Cullinan Therapeutics Inc benefit from AI trends2026 Fed Impact & Capital Protection Trade Alerts - baoquankhu1.vn

Mar 26, 2026

Mar 24, 2026

Clear Street reiterates Cullinan Oncology stock rating on Gilead deal validation - Investing.com

Mar 24, 2026

Potential of Cullinan Therapeutics (CGEM) Highlighted by Recent Acquisition - GuruFocus

Mar 24, 2026

Mar 21, 2026

Swing Trade: Does Cullinan Therapeutics Inc have strong EBITDA marginsMarket Risk Analysis & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn

Mar 21, 2026

Mar 20, 2026

Cullinan Therapeutics to lead new discussions on next-generation immune therapies - Traders Union

Mar 20, 2026

Mar 18, 2026

Decliners Report: What is Cullinan Therapeutics Incs valuation compared to sector2026 PostEarnings & Target Return Focused Picks - baoquankhu1.vn

Mar 18, 2026

Mar 17, 2026

Rate Cut: Whats the RSI of Cullinan Therapeutics Inc stockMarket Activity Summary & Daily Chart Pattern Signal Reports - baoquankhu1.vn

Mar 17, 2026

Mar 16, 2026

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Mar 16, 2026

Mar 14, 2026

Cullinan Therapeutics flags 2026 as “defining year” at Leerink, tees up key CLN-978/CLN-049 data - MarketBeat

Mar 14, 2026

Mar 12, 2026

Whale Trades: Can Cullinan Therapeutics Inc outperform under higher oil pricesDividend Hike & Free Safe Capital Growth Stock Tips - baoquankhu1.vn

Mar 12, 2026

Guggenheim Reaffirms Their Buy Rating on Cullinan Management (CGEM) - The Globe and Mail

Mar 12, 2026

Mar 11, 2026

Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI), Cullinan Management (CGEM) and Pfizer (PFE) - The Globe and Mail

Mar 11, 2026

Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Expected to Rise, Wedbush Analyst Says - MarketBeat

Mar 11, 2026

Cullinan Therapeutics (CGEM): Wedbush Raises Price Target to $36 - GuruFocus

Mar 11, 2026

Cullinan Therapeutics Reports 2025 Financial Results, Updates on CLN-978, Zipalertinib NDA, and 2026 Clinical Milestones - Minichart

Mar 11, 2026

Mar 10, 2026

CGEM: Key T-cell engager programs advance toward pivotal milestones and data readouts in 2026 - TradingView

Mar 10, 2026

Cullinan Therapeutics: Q4 Earnings InsightsCullinan Therapeutics (NASDAQ:CGEM) - Benzinga

Mar 10, 2026

CGEM: 2026 will be pivotal with key data and regulatory milestones for lead T-cell engager programs - TradingView

Mar 10, 2026

Cullinan Oncology (CGEM) Projects Strong Cash Position into 2029 - GuruFocus

Mar 10, 2026

Stifel raises Cullinan Oncology stock price target on autoimmune progress By Investing.com - Investing.com India

Mar 10, 2026